検索結果 - C. Oliver Hanemann

結果の絞り込み
  1. 1
    Magic but treatable? Tumours due to loss of Merlin

    Magic but treatable? Tumours due to loss of Merlin 著者: C. Oliver Hanemann

    出版事項 2007
    全文の入手 全文の入手
    Revisão
    お気に入りに追加
    保存先:
  2. 2
    Merlin, a multi‐suppressor from cell membrane to the nucleus

    Merlin, a multi‐suppressor from cell membrane to the nucleus 著者: Lü Zhou, C. Oliver Hanemann

    出版事項 2012
    全文の入手
    Revisão
    お気に入りに追加
    保存先:
  3. 3
    Schwannomas and Their Pathogenesis

    Schwannomas and Their Pathogenesis 著者: David A. Hilton, C. Oliver Hanemann

    出版事項 2014
    全文の入手
    Revisão
    お気に入りに追加
    保存先:
  4. 4
    The Tumor Suppressor Merlin Controls Growth in Its Open State, and Phosphorylation Converts It to a Less-Active More-Closed State

    The Tumor Suppressor Merlin Controls Growth in Its Open State, and Phosphorylation Converts It to a Less-Active More-Closed State 著者: Ifat Sher, C. Oliver Hanemann, P. Andrew Karplus, Anthony Bretscher

    出版事項 2012
    全文の入手
    Carta
    お気に入りに追加
    保存先:
  5. 5
    Δ<sup>9</sup>‐tetrahydrocannabinol (Δ<sup>9</sup>‐THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease

    Δ<sup>9</sup>‐tetrahydrocannabinol (Δ<sup>9</sup>‐THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease 著者: Camille Carroll, Marie‐Louise Zeissler, C. Oliver Hanemann, John Zajicek

    出版事項 2012
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  6. 6
    Dissecting and Targeting the Growth Factor–Dependent and Growth Factor–Independent Extracellular Signal-Regulated Kinase Pathway in Human Schwannoma

    Dissecting and Targeting the Growth Factor–Dependent and Growth Factor–Independent Extracellular Signal-Regulated Kinase Pathway in Human Schwannoma 著者: Sylwia Ammoun, Christine Flaiz, Natalia Ristic, Jennifer Schuldt, C. Oliver Hanemann

    出版事項 2008
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  7. 7
    Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2

    Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2 著者: Sylwia Ammoun, M. Caroline Schmid, J. Triner, Paul W. Manley, C. Oliver Hanemann

    出版事項 2011
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  8. 8
    Merlin-Deficient Human Tumors Show Loss of Contact Inhibition and Activation of Wnt/β-Catenin Signaling Linked to the PDGFR/Src and Rac/PAK Pathways

    Merlin-Deficient Human Tumors Show Loss of Contact Inhibition and Activation of Wnt/β-Catenin Signaling Linked to the PDGFR/Src and Rac/PAK Pathways 著者: Lü Zhou, Emanuela Ercolano, Sylwia Ammoun, M. Caroline Schmid, Magdalena Barczyk, C. Oliver Hanemann

    出版事項 2011
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  9. 9
    Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2

    Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2 著者: A.D Sperfeld, Claudine Hein, J. M. Schröder, Albert C. Ludolph, C. Oliver Hanemann

    出版事項 2002
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  10. 10
    Accumulation of autophagosomes confers cytotoxicity

    Accumulation of autophagosomes confers cytotoxicity 著者: Robert W. Button, Sheridan L. Roberts, Thea L. Willis, C. Oliver Hanemann, Shouqing Luo

    出版事項 2017
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  11. 11
    Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis

    Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis 著者: Marie‐Louise Zeissler, Jordan Eastwood, Kieran McCorry, C. Oliver Hanemann, John Zajicek, Camille Carroll

    出版事項 2016
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  12. 12
    Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical Use

    Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical Use 著者: Chetan Bettegowda, Meena Upadhayaya, D. Gareth Evans, AeRang Kim, Dimitrios Mathios, C. Oliver Hanemann

    出版事項 2021
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  13. 13
    Artesunate induces necrotic cell death in schwannoma cells

    Artesunate induces necrotic cell death in schwannoma cells 著者: Robert W. Button, Fang Lin, Emanuela Ercolano, Joseph H. Vincent, Bing Hu, C. Oliver Hanemann, Shouqing Luo

    出版事項 2014
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  14. 14
    Tumour-associated macrophage infiltration differs in meningioma genotypes, and is important in tumour dynamics

    Tumour-associated macrophage infiltration differs in meningioma genotypes, and is important in tumour dynamics 著者: Ting Zhang, Claire Adams, György Fejér, Emanuela Ercolano, Jonathan Cutajar, Juri Na, Felix Sahm, C. Oliver Hanemann

    出版事項 2025
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  15. 15
    Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival

    Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival 著者: Sylwia Ammoun, Lucy Provenzano, Lü Zhou, Magdalena Barczyk, Kevin Gregory-Evans, David A. Hilton, Sassan Hafizi, C. Oliver Hanemann

    出版事項 2013
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  16. 16
    Proteomic analysis discovers the differential expression of novel proteins and phosphoproteins in meningioma including NEK9, HK2 and SET and deregulation of RNA metabolism

    Proteomic analysis discovers the differential expression of novel proteins and phosphoproteins in meningioma including NEK9, HK2 and SET and deregulation of RNA metabolism 著者: Jemma Dunn, Sara Ferluga, Vikram Sharma, Matthias E. Futschik, David A. Hilton, Claire Adams, Edwin Lasonder, C. Oliver Hanemann

    出版事項 2018
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  17. 17
    Tetracycline-inducible transgene expression mediated by a single AAV vector

    Tetracycline-inducible transgene expression mediated by a single AAV vector 著者: A. Chtarto, Hans‐Ulrich Bender, C. Oliver Hanemann, Tim J. Kemp, Enni Lehtonen, Marc Levivier, Jacques Brotchi, Thierry Velu, Liliane Tenenbaum

    出版事項 2003
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  18. 18
    ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma

    ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma 著者: Sylwia Ammoun, Clare H. Cunliffe, Jeffrey C. Allen, Luis Chiriboga, Filippo G. Giancotti, David Zagzag, C. Oliver Hanemann, Matthias A. Karajannis

    出版事項 2010
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  19. 19
    Achieving consensus for clinical trials

    Achieving consensus for clinical trials 著者: Scott R. Plotkin, Jaishri O. Blakeley, Eva Dombi, Michael J. Fisher, C. Oliver Hanemann, Karin S. Walsh, Pamela L. Wolters, Brigitte C. Widemann

    出版事項 2013
    全文の入手 全文の入手
    Revisão
    お気に入りに追加
    保存先:
  20. 20
    Merlin/NF2 Loss-Driven Tumorigenesis Linked to CRL4DCAF1-Mediated Inhibition of the Hippo Pathway Kinases Lats1 and 2 in the Nucleus

    Merlin/NF2 Loss-Driven Tumorigenesis Linked to CRL4DCAF1-Mediated Inhibition of the Hippo Pathway Kinases Lats1 and 2 in the Nucleus 著者: Wei Li, Jonathan M. Cooper, Lü Zhou, Chenyi Yang, Hediye Erdjument‐Bromage, David Zagzag, Matija Snuderl, Marc Ladanyi, C. Oliver Hanemann, Pengbo Zhou, Matthias A. Karajannis, Filippo G. Giancotti

    出版事項 2014
    全文の入手
    Artigo
    お気に入りに追加
    保存先:

検索ツール: